Page last updated: 2024-11-05

bunamidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Bunamidine is an antiparasitic drug used to treat coccidiosis in poultry. It is a synthetic compound with the chemical name 1,4-dihydro-4-oxo-6-(2-pyridinyl)-2-pyrimidinecarboxamide. Bunamidine is effective against a variety of coccidia species, including Eimeria tenella, E. acervulina, E. brunetti, and E. maxima. It is thought to act by interfering with the parasite's metabolic pathways, specifically by inhibiting the synthesis of folic acid. Bunamidine is typically administered to poultry via feed or water, and it is generally well-tolerated. However, some side effects have been reported, such as reduced egg production and changes in liver enzymes. Bunamidine is an important drug for the control of coccidiosis in poultry, which can cause significant economic losses to the poultry industry. Research on bunamidine continues to focus on understanding its mechanism of action and developing new formulations to improve its efficacy and reduce the potential for resistance.'

bunamidine: veterinary anti-platyhelmintic agent used for taenia infestations; minor descriptor (75-85); on-line & Index Medicus search AMIDINES (75-85); RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13986
CHEMBL ID1355596
SCHEMBL ID666728
MeSH IDM0263060

Synonyms (33)

Synonym
n,n-dibutyl-4-hexoxy-naphthalene-1-carboxamidine
n,n-dibutyl-4-(hexyloxy)-1-naphthalenecarboximidamide
n, n-dibutyl-4-(hexyloxy)-1-naphthamidine monohydrochloride
1-naphthamidine, n, n-dibutyl-4-(hexyloxy)-, monohydrochloride
n, n-dibutyl-4-(hexyloxy)-1-naphthamidine hydrochloride
n, n-dibutyl-4-(hexyloxy)-1-naphthamidine-
bunamidine
bunamidine (usan)(*hydrochloride*)
n,n-dibutyl-4-hexoxynaphthalene-1-carboximidamide
bunamidin
bunamidine [inn:ban]
n,n-dibutyl-4-hexyloxy-1-naphthamidin
1-naphthalenecarboximidamide, n,n-dibutyl-4-(hexyloxy)-
bunamidinum
a9iw1g3p6c ,
n,n-dibutyl-4-(hexyloxy)-1-naphthamidine
bunamidina
bunamidina [inn-spanish]
unii-a9iw1g3p6c
3748-77-4
bunamidinum [inn-latin]
bunamidine [mi]
bunamidine [inn]
CHEMBL1355596
SCHEMBL666728
DTXSID4048272
tox21 112707
1-naphthamidine, n,n-dibutyl-4-(hexyloxy)-
n,n-dibutyl-4-hexyloxy-1-naphthamidine
n,n-dibutyl-4-(hexyloxy)naphthalene-1-carboximidamide
FGGFIMIICGZCCJ-UHFFFAOYSA-N
DB11501
Q27273807
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency17.78280.141337.9142100.0000AID1490
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID504865
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.77830.035520.977089.1251AID504332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency31.62280.354828.065989.1251AID504847
huntingtin isoform 2Homo sapiens (human)Potency35.48130.000618.41981,122.0200AID1688
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency31.62280.010323.856763.0957AID2662
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency28.93420.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency12.61080.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency23.94670.005612.367736.1254AID624032; AID624044
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency39.81070.060110.745337.9330AID492961
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1131693Anthelmintic activity against Hymenolepis nana infected in mouse assessed as reduction in worm burden at 100 mg/kg bid for 5 days relative to control1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Imidazo[4,5-f]quinolines. 4. Synthesis and anthelmintic activity of a series of imidazo[4,5-f]quinolin-9-ols.
AID1131699Toxicity in mouse infected with Hymenolepis nana at 300 mg/kg bid for 5 days1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Imidazo[4,5-f]quinolines. 4. Synthesis and anthelmintic activity of a series of imidazo[4,5-f]quinolin-9-ols.
AID1134304Anthelmintic activity against Hymenolepis nana infected in mouse assessed as reduction in worm burden at 25 mg/kg administered bid for 3 days relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Imidazo[4,5-f]quinolines. 2. A series of 9-(substituted amino)imidazo[4,5-f]quinolines as antitapeworm agents.
AID1131694Anthelmintic activity against Hymenolepis nana infected in mouse assessed as reduction in worm burden at 50 mg/kg bid for 5 days relative to control1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Imidazo[4,5-f]quinolines. 4. Synthesis and anthelmintic activity of a series of imidazo[4,5-f]quinolin-9-ols.
AID1134305Anthelmintic activity against Hymenolepis nana infected in mouse assessed as reduction in worm burden at 10 mg/kg administered bid for 3 days relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Imidazo[4,5-f]quinolines. 2. A series of 9-(substituted amino)imidazo[4,5-f]quinolines as antitapeworm agents.
AID1134303Anthelmintic activity against Hymenolepis nana infected in mouse assessed as reduction in worm burden at 50 mg/kg administered bid for 3 days relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Imidazo[4,5-f]quinolines. 2. A series of 9-(substituted amino)imidazo[4,5-f]quinolines as antitapeworm agents.
AID1131696Anthelmintic activity against Hymenolepis nana infected in mouse assessed as reduction in worm burden at 10 mg/kg bid for 5 days relative to control1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Imidazo[4,5-f]quinolines. 4. Synthesis and anthelmintic activity of a series of imidazo[4,5-f]quinolin-9-ols.
AID1134302Anthelmintic activity against Hymenolepis nana infected in mouse assessed as reduction in worm burden at 100 mg/kg administered bid for 3 days relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Imidazo[4,5-f]quinolines. 2. A series of 9-(substituted amino)imidazo[4,5-f]quinolines as antitapeworm agents.
AID1131695Anthelmintic activity against Hymenolepis nana infected in mouse assessed as reduction in worm burden at 25 mg/kg bid for 5 days relative to control1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Imidazo[4,5-f]quinolines. 4. Synthesis and anthelmintic activity of a series of imidazo[4,5-f]quinolin-9-ols.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (66.67)18.7374
1990's1 (11.11)18.2507
2000's1 (11.11)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.29 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (11.11%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]